Loading...
Loading...
Browse all stories on DeepNewz
Visit£40 Antidepressant Vortioxetine Found Effective Against Glioblastomas in ETH Zurich Study
Sep 20, 2024, 10:29 AM
Researchers have discovered that vortioxetine, a widely available antidepressant costing £40, shows unexpected effectiveness in treating glioblastomas, the most common and aggressive type of brain tumour. Studies conducted in cell cultures and mice by ETH Zurich and other research teams demonstrated that the drug can shrink tumours and kill tumour cells. This breakthrough suggests that vortioxetine could be repurposed to combat glioblastomas, offering a potentially new treatment avenue for this deadly brain cancer.
View original story
Markets
Yes • 50%
No • 50%
Clinical trial registries, ETH Zurich announcements, or reputable medical news sources
No • 50%
Yes • 50%
FDA announcements, reputable medical news sources
No • 50%
Yes • 50%
Published clinical trial results, ETH Zurich announcements, or reputable medical journals
Positive results • 25%
Trial halted or delayed • 25%
Inconclusive results • 25%
Negative results • 25%
Published clinical trial results, ETH Zurich announcements, or reputable medical journals
Not approved • 25%
Approved by FDA • 25%
Approved by EMA • 25%
Approved by both FDA and EMA • 25%
FDA announcements, EMA announcements, other regulatory bodies' announcements
Pfizer • 25%
Roche • 25%
Novartis • 25%
Other • 25%
Financial news reports, company press releases